Ariclaim
duloxetine
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Ariclaim has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 07/08/2018
Authorisation details
| Product details | |
|---|---|
| Name |
Ariclaim
|
| Agency product number |
EMEA/H/C/000552
|
| Active substance |
duloxetine
|
| International non-proprietary name (INN) or common name |
duloxetine
|
| Therapeutic area (MeSH) |
Diabetic Neuropathies
|
| Anatomical therapeutic chemical (ATC) code |
N06AX21
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Eli Lilly Nederland B.V.
|
| Revision |
26
|
| Date of issue of marketing authorisation valid throughout the European Union |
11/08/2004
|
| Contact address |
Papendorpseweg 83 |
Product information
09/12/2016 Ariclaim - EMEA/H/C/000552 - N/0066
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Psychoanaleptics
Therapeutic indication
Therapeutic indication
Treatment of diabetic peripheral neuropathic pain.
Ariclaim is indicated in adults.